Cytokinetics, Incorporated (CYTK) is preparing to unveil the first topline data from ACACIA-HCM, its pivotal Phase 3 clinical trial evaluating Aficamten in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).
The company will release results today, May 5, 2026, followed by an investor and analyst conference call at 8:00 AM Eastern Time.
Aficamten, a next-generation cardiac myosin inhibitor marketed as MYQORZO for obstructive HCM, is approved in the U.S., Europe, and China. ACACIA-HCM is designed to assess whether the therapy can also benefit patients with the non-obstructive form of the disease, a population with limited treatment options and persistent symptoms despite standard care.
Cytokinetics, a cardiovascular-focused biopharmaceutical company, with more than 25 years of research in muscle biology, continues to advance a pipeline that includes investigational agents such as Omecamtiv mecarbil and Ulacamten for various forms of heart failure.
The ACACIA-HCM topline readout marks a significant milestone for the company as it evaluates Aficamten's potential to expand beyond obstructive HCM and address a broader patient population.
CYTK has traded between $29.31 and $70.98 over the past year. The stock closed Monday's trading at $66.05, up 4.26%. During overnight trading, the stock traded at $66.80, up 1.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.